Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network

E. Hoster, A. Rosenwald, F. Berger, HW. Bernd, S. Hartmann, C. Loddenkemper, TF. Barth, N. Brousse, S. Pileri, G. Rymkiewicz, R. Kodet, S. Stilgenbauer, R. Forstpointner, C. Thieblemont, M. Hallek, B. Coiffier, U. Vehling-Kaiser, R. Bouabdallah,...

. 2016 ; 34 (12) : 1386-94. [pub] 20160229

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, webové vysílání

Perzistentní odkaz   https://www.medvik.cz/link/bmc16027622

PURPOSE: Mantle-cell lymphoma (MCL) is a rather aggressive B-cell malignancy whose considerable variability of individual outcome is associated with clinical characteristics (Mantle Cell Lymphoma International Prognostic Index [MIPI]). The Ki-67 index is a strong independent prognostic factor; however, the biologic MIPI (MIPI-b) distinguishes only two groups, which does not appropriately depict the clinical heterogeneity. By using the cohort from the European MCL Younger and MCL Elderly trials, we aimed to evaluate the additional prognostic impact of cytology and growth pattern and to improve risk stratification with the Ki-67 index and MIPI. PATIENTS AND METHODS: Diagnostic tumor biopsies were reviewed by the European Mantle Cell Lymphoma Pathology Panel to determine Ki-67 index by using published guidelines, cytology, and growth pattern. We evaluated prognostic effects for overall survival (OS) by Cox regression. For the cohort used for MIPI-b development (German Low-Grade Lymphoma Study Group [GLSG] 1996 and GLSG2000), we checked whether the equally weighted combination of Ki-67 index (dichotomized at the validated 30% cutoff) and MIPI risk groups was adequate and compared the prognostic power of this modified combination to MIPI and MIPI-b for the MCL Younger/MCL Elderly cohort. RESULTS: The Ki-67 index was assessed in 508 of 832 patients (median age, 62 years). Blastoid cytology was associated with inferior OS independently of MIPI but not independently of the Ki-67 index. Growth pattern was not independently prognostic. The modified combination of the Ki-67 index and MIPI separated four groups with 5-year OS: 85%, 72%, 43%, and 17% (P < .001) and was more discriminative than MIPI and MIPI-b. CONCLUSION: Using the Ki-67 index is superior to using cytology and growth pattern as prognostic factors in MCL. The modified combination of the Ki-67 index and MIPI showed a refined risk stratification, reflecting their strong complementary prognostic effects while integrating the most relevant prognostic factors available in clinical routine.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16027622
003      
CZ-PrNML
005      
20240416112506.0
007      
ta
008      
161005s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.2015.63.8387 $2 doi
024    7_
$a 10.1200/JCO.2015.63.8387 $2 doi
035    __
$a (PubMed)26926679
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hoster, Eva $u University Hospital Munich; Eva Hoster, University of Munich, Munich; eva.hoster@med.uni-muenchen.de.
245    10
$a Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network / $c E. Hoster, A. Rosenwald, F. Berger, HW. Bernd, S. Hartmann, C. Loddenkemper, TF. Barth, N. Brousse, S. Pileri, G. Rymkiewicz, R. Kodet, S. Stilgenbauer, R. Forstpointner, C. Thieblemont, M. Hallek, B. Coiffier, U. Vehling-Kaiser, R. Bouabdallah, L. Kanz, M. Pfreundschuh, C. Schmidt, V. Ribrag, W. Hiddemann, M. Unterhalt, JC. Kluin-Nelemans, O. Hermine, MH. Dreyling, W. Klapper,
520    9_
$a PURPOSE: Mantle-cell lymphoma (MCL) is a rather aggressive B-cell malignancy whose considerable variability of individual outcome is associated with clinical characteristics (Mantle Cell Lymphoma International Prognostic Index [MIPI]). The Ki-67 index is a strong independent prognostic factor; however, the biologic MIPI (MIPI-b) distinguishes only two groups, which does not appropriately depict the clinical heterogeneity. By using the cohort from the European MCL Younger and MCL Elderly trials, we aimed to evaluate the additional prognostic impact of cytology and growth pattern and to improve risk stratification with the Ki-67 index and MIPI. PATIENTS AND METHODS: Diagnostic tumor biopsies were reviewed by the European Mantle Cell Lymphoma Pathology Panel to determine Ki-67 index by using published guidelines, cytology, and growth pattern. We evaluated prognostic effects for overall survival (OS) by Cox regression. For the cohort used for MIPI-b development (German Low-Grade Lymphoma Study Group [GLSG] 1996 and GLSG2000), we checked whether the equally weighted combination of Ki-67 index (dichotomized at the validated 30% cutoff) and MIPI risk groups was adequate and compared the prognostic power of this modified combination to MIPI and MIPI-b for the MCL Younger/MCL Elderly cohort. RESULTS: The Ki-67 index was assessed in 508 of 832 patients (median age, 62 years). Blastoid cytology was associated with inferior OS independently of MIPI but not independently of the Ki-67 index. Growth pattern was not independently prognostic. The modified combination of the Ki-67 index and MIPI separated four groups with 5-year OS: 85%, 72%, 43%, and 17% (P < .001) and was more discriminative than MIPI and MIPI-b. CONCLUSION: Using the Ki-67 index is superior to using cytology and growth pattern as prognostic factors in MCL. The modified combination of the Ki-67 index and MIPI showed a refined risk stratification, reflecting their strong complementary prognostic effects while integrating the most relevant prognostic factors available in clinical routine.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a biopsie $7 D001706
650    12
$a proliferace buněk $7 D049109
650    _2
$a diskriminační analýza $7 D016002
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a imunohistochemie $7 D007150
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a antigen Ki-67 $x analýza $7 D019394
650    _2
$a lymfom z plášťových buněk $x chemie $x mortalita $x patologie $x terapie $7 D020522
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a multivariační analýza $7 D015999
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    _2
$a časové faktory $7 D013997
650    _2
$a tumor burden $7 D047368
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a webové vysílání $7 D057405
700    1_
$a Rosenwald, Andreas $u University of Würzburg, Würzburg
700    1_
$a Berger, Françoise $u LYSA Group
700    1_
$a Bernd, Heinz-Wolfram $u University Hospital Schleswig-Holstein, Lübeck
700    1_
$a Hartmann, Sylvia $u University Hospital of Frankfurt, Frankfurt am Main
700    1_
$a Loddenkemper, Christoph $u University Hospital Berlin Charité
700    1_
$a Barth, Thomas F E $u University Medical Center Ulm
700    1_
$a Brousse, Nicole, $d 1947- $u Hopital Necker $7 xx0316095
700    1_
$a Pileri, Stefano $u University of Bologna, Bologna, Italy
700    1_
$a Rymkiewicz, Grzegorz $u The Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
700    1_
$a Kodet, Roman $u Charles University, Prague, Czech Republic
700    1_
$a Stilgenbauer, Stephan $u University of Ulm, Ulm
700    1_
$a Forstpointner, Roswitha $u University Hospital Munich
700    1_
$a Thieblemont, Catherine $u Hôpital Saint Louis
700    1_
$a Hallek, Michael $u Universität zu Köln, Köln
700    1_
$a Coiffier, Bertrand, $d 1947-2019 $u Centre Hospitalier Lyon-Sud, Pierre-Bénité $7 xx0314848
700    1_
$a Vehling-Kaiser, Ursula $u Tagesklinik Hämatologie Onkologie, Landshut
700    1_
$a Bouabdallah, Réda $u Service d'Hématologie, Marseille
700    1_
$a Kanz, Lothar $u University of Tübingen, Tübingen
700    1_
$a Pfreundschuh, Michael $u Universitätsklinik des Saarlandes, Hamburg
700    1_
$a Schmidt, Christian $u University Hospital Munich
700    1_
$a Ribrag, Vincent $u Institut Gustave Roussy, Villejuif, France
700    1_
$a Hiddemann, Wolfgang $u University Hospital Munich
700    1_
$a Unterhalt, Michael $u University Hospital Munich
700    1_
$a Kluin-Nelemans, Johanna C $u University of Groningen, Groningen, The Netherlands
700    1_
$a Hermine, Olivier $u Université Sorbonne Paris Cité, Paris
700    1_
$a Dreyling, Martin H $u University Hospital Munich
700    1_
$a Klapper, Wolfram $u University of Kiel, Kiel, Germany
773    0_
$w MED00002596 $t Journal of clinical oncology $x 1527-7755 $g Roč. 34, č. 12 (2016), s. 1386-94
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26926679 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20240416112503 $b ABA008
999    __
$a ok $b bmc $g 1165936 $s 952252
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 34 $c 12 $d 1386-94 $e 20160229 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20161005

Najít záznam

Citační ukazatele

Možnosti archivace